Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Total debt
Biogen Inc.'s total debt at the end of fiscal 2025 was $6.3B, up 38.3% from $4.5B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $7.3B. Over the past ten years it has ranged from $4.5B (fiscal 2019) to $7.4B (fiscal 2020); the current reading is higher than 64% of that period. Biogen Inc. ranks 16th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $6.3B | 38.26% |
| FY2024 | $4.5B | (33.01%) |
| FY2023 | $6.8B | 8.08% |
| FY2022 | $6.3B | 0.11% |
| FY2021 | $6.3B | (15.52%) |
| FY2020 | $7.4B | 66.54% |
| FY2019 | $4.5B | (24.89%) |
| FY2018 | $5.9B | 0.03% |
| FY2017 | $5.9B | (8.87%) |
| FY2016 | $6.5B | (0.13%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $7.3B | 15.93% |
| Mar 2026 | $6.3B | 0.03% |
| Dec 2025 | $6.3B | 0.03% |
| Sep 2025 | $6.3B | 0.02% |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $63.2B |
| AMGN Amgen Inc. compare | $57.3B |
| BMY Bristol Myers Squibb Company compare | $43.1B |
| AZN AstraZeneca PLC compare | $29.5B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| SNY Sanofi compare | $25.2B |
| GSK GSK PLC Sponsored ADR compare | $24.5B |
| NVO Novo Nordisk A/S compare | $21.8B |
| BIIB Biogen Inc. | $7.3B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement